Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
The biopharmaceutical industry in China, like the rest of the world, was forced to swiftly adopt decentralized clinical trial (DCT) approaches to maintain progress during to the COVID-19 pandemic. And, like the rest of the world, its patients, investigators and sponsors were hopeful about the benefits of using these tools.
Two new surveys conducted by IQVIA in China found patients are overwhelmingly open to participating in fully decentralized as well as hybrid virtual trials, and to using wearables, electronic data collection and other digital tools as part of that experience.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.